...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
【24h】

Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.

机译：绝经前激素反应性乳腺癌，广泛涉及腋窝淋巴结：完全雌激素阻滞和化疗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Poor prognosis is associated with estrogen- and/or progesterone receptor-positive (ER(+), PGR(+)) premenopausal breast cancer (PM-BC) with high Ki-67 labeling index and extensive axillary lymph node involvement. The role of adjuvant chemotherapy (CT) and hormonal therapy have not yet been established in these patients. PATIENTS AND METHODS: Twenty-five PM-BC patients received, in sequence, leuprorelin, taxane-anthracycline induction chemotherapy, radiation therapy, a platinum-based intensification high-dose CT, followed by leuprorelin and anastrazole for five years. Vascular endothelial growth factor (VEGF) levels were measured as the primary end-point; secondary end-points were 10-year relapse-free survival (RFS) and overall survival (OS) rates. RESULTS: The median patient age was 44 years, and the mean number of positive axillary nodes was 14. All patients were ER(+) and/or PGR(+), with a median Ki-67 index of 33%. Five patients were Cerb-B2 positive. Grade 4 hematologic toxicity was observed in all patients, no patient showed a decrease of cardiac ejection fraction and hot flashes and arthralgias were of moderate intensity. After a median follow-up of 70 months, VEGF levels significantly decreased (p<0.001); 10-year RFS and OS were 76% and 78%, respectively. CONCLUSION: Total estrogen blockade and high-dose CT in PM-BC patients is feasible, has moderate toxicity, significantly reduces VEGF levels, and seems to improve the expected RFS and OS.
机译：背景：预后不良与具有高Ki-67标记指数和广泛腋窝淋巴结转移的雌激素和/或孕激素受体阳性（ER（+），PGR（+））绝经前乳腺癌（PM-BC）相关。在这些患者中辅助化疗（CT）和激素治疗的作用尚未确定。患者和方法：25例PM-BC患者依次接受亮丙瑞林，紫杉烷-蒽环类诱导化疗，放疗，铂基强化大剂量CT，然后接受亮丙瑞林和阿那曲唑治疗五年。测量血管内皮生长因子（VEGF）水平作为主要终点;次要终点是10年无复发生存率（RFS）和总生存率（OS）。结果：患者中位年龄为44岁，平均腋窝淋巴结转移阳性平均数为14。所有患者均为ER（+）和/或PGR（+），中位Ki-67指数为33％。 5例患者为Cerb-B2阳性。在所有患者中均观察到4级血液学毒性，没有患者显示出心脏射血分数降低，潮热和关节痛为中等强度。在中位随访70个月后，VEGF水平显着降低（p <0.001）。 10年的RFS和OS分别为76％和78％。结论：PM-BC患者完全雌激素阻断和大剂量CT检查是可行的，具有中等毒性，可显着降低VEGF水平，并有望改善预期的RFS和OS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号